FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083670462> ?p ?o ?g. }

• W2083670462 abstract "The phosphoinositide 3-kinase (PI3K) signaling pathway is the most commonly dysregulated pathway in many human cancers, including non-small cell lung cancer (NSCLC). Therefore, targeting PI3K signaling has become a promising approach in cancer therapy. Although studies have indicated development of resistance to PI3K inhibitors, the molecular mechanism of drug resistance is largely unknown in NSCLC. Here, we sought to identify new potential biomarkers and pathways that confer resistance to PI3K inhibitors in NSCLC. To this end, we used reverse-phase protein array (RPPA) to assess the expression levels and activation status of 137 proteins involved in signaling pathways implicated in lung cancer. Seventy-four NSCLC cell lines were treated with the PI3K inhibitor BAY 80-6946 and lysates were collected for proteomic analysis. First, we evaluted the association between drug sensitivity (IC50) and RPPA expression levels at baseline in sixty NSCLC cell lines. Correlation test was applied to each marker vs drug and Wilcox Rank test was performed to compare the smallest and largest one third of all the cell lines. We found increased phosphorylation and inactivation of pro-apoptotic protein Bad and phospho-LKB1 in the resistant cell lines. An inverse correlation was found for phosphorylation and inactivation of c-Src. Interestingly, activation of EGFR and increased levels of PTCH and PKCα were found in the resistant cell lines. Next, paired t-test was applied to each marker comparing the difference between drug and control treated cells. As expected, treatment with BAY 80-6946, significantly downregulates components of PI3K/mTOR pathway, as illustrated by decreased levels of phospho-Akt (-4.28-fold relative expression) and phospho-S6 ribosomal protein (-9.64-fold), phospho-p70S6K (-3.47-fold) and phospho-mTOR (-1.42-fold). We observed elevated expression of negative regulators of mTOR pathway, LKB1 (1.11-fold), AMPKα (1.12-fold) and phospho-AMPKα (12-fold). On the other hand, our analysis identified new potential pathways of resistance that are activated upon PI3K inhibition. We found increased levels of phospho-EGFR (P Citation Format: Maria A. Cortez, Lauren Averett Byers, You Hong Fan, Lixia Diao, Philip Groth, Julianne Paul, Jing Wang, Uma Giri, Jayanthi Gudikote, Hai Tran, Kevin Coombes, John D. Minna, Ningshu Liu, John V. Heymach. Proteomic analysis reveals Src/Stat and EGFR/MAPK pathways as potential mechanism of resistance to PI3K inhibitors in lung cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2498. doi:10.1158/1538-7445.AM2013-2498" @default.
• W2083670462 created "2016-06-24" @default.
• W2083670462 creator A5028358775 @default.
• W2083670462 creator A5034595514 @default.
• W2083670462 creator A5037677450 @default.
• W2083670462 creator A5048380048 @default.
• W2083670462 creator A5048865240 @default.
• W2083670462 creator A5056267838 @default.
• W2083670462 creator A5059903431 @default.
• W2083670462 creator A5066245619 @default.
• W2083670462 creator A5066837969 @default.
• W2083670462 creator A5067755477 @default.
• W2083670462 creator A5073051489 @default.
• W2083670462 creator A5074180677 @default.
• W2083670462 creator A5079259757 @default.
• W2083670462 creator A5080830668 @default.
• W2083670462 date "2013-04-15" @default.
• W2083670462 modified "2023-09-27" @default.
• W2083670462 title "Abstract 2498: Proteomic analysis reveals Src/Stat and EGFR/MAPK pathways as potential mechanism of resistance to PI3K inhibitors in lung cancer." @default.
• W2083670462 doi "https://doi.org/10.1158/1538-7445.am2013-2498" @default.
• W2083670462 hasPublicationYear "2013" @default.
• W2083670462 type Work @default.
• W2083670462 sameAs 2083670462 @default.
• W2083670462 citedByCount "0" @default.
• W2083670462 crossrefType "proceedings-article" @default.
• W2083670462 hasAuthorship W2083670462A5028358775 @default.
• W2083670462 hasAuthorship W2083670462A5034595514 @default.
• W2083670462 hasAuthorship W2083670462A5037677450 @default.
• W2083670462 hasAuthorship W2083670462A5048380048 @default.
• W2083670462 hasAuthorship W2083670462A5048865240 @default.
• W2083670462 hasAuthorship W2083670462A5056267838 @default.
• W2083670462 hasAuthorship W2083670462A5059903431 @default.
• W2083670462 hasAuthorship W2083670462A5066245619 @default.
• W2083670462 hasAuthorship W2083670462A5066837969 @default.
• W2083670462 hasAuthorship W2083670462A5067755477 @default.
• W2083670462 hasAuthorship W2083670462A5073051489 @default.
• W2083670462 hasAuthorship W2083670462A5074180677 @default.
• W2083670462 hasAuthorship W2083670462A5079259757 @default.
• W2083670462 hasAuthorship W2083670462A5080830668 @default.
• W2083670462 hasConcept C11960822 @default.
• W2083670462 hasConcept C121608353 @default.
• W2083670462 hasConcept C126322002 @default.
• W2083670462 hasConcept C143998085 @default.
• W2083670462 hasConcept C2776256026 @default.
• W2083670462 hasConcept C502942594 @default.
• W2083670462 hasConcept C57074206 @default.
• W2083670462 hasConcept C62478195 @default.
• W2083670462 hasConcept C71924100 @default.
• W2083670462 hasConcept C75217442 @default.
• W2083670462 hasConcept C86554907 @default.
• W2083670462 hasConcept C86803240 @default.
• W2083670462 hasConcept C95444343 @default.
• W2083670462 hasConcept C98274493 @default.
• W2083670462 hasConceptScore W2083670462C11960822 @default.
• W2083670462 hasConceptScore W2083670462C121608353 @default.
• W2083670462 hasConceptScore W2083670462C126322002 @default.
• W2083670462 hasConceptScore W2083670462C143998085 @default.
• W2083670462 hasConceptScore W2083670462C2776256026 @default.
• W2083670462 hasConceptScore W2083670462C502942594 @default.
• W2083670462 hasConceptScore W2083670462C57074206 @default.
• W2083670462 hasConceptScore W2083670462C62478195 @default.
• W2083670462 hasConceptScore W2083670462C71924100 @default.
• W2083670462 hasConceptScore W2083670462C75217442 @default.
• W2083670462 hasConceptScore W2083670462C86554907 @default.
• W2083670462 hasConceptScore W2083670462C86803240 @default.
• W2083670462 hasConceptScore W2083670462C95444343 @default.
• W2083670462 hasConceptScore W2083670462C98274493 @default.
• W2083670462 hasLocation W20836704621 @default.
• W2083670462 hasOpenAccess W2083670462 @default.
• W2083670462 hasPrimaryLocation W20836704621 @default.
• W2083670462 hasRelatedWork W1414975042 @default.
• W2083670462 hasRelatedWork W1601243762 @default.
• W2083670462 hasRelatedWork W2164425430 @default.
• W2083670462 hasRelatedWork W2312380641 @default.
• W2083670462 hasRelatedWork W2341957938 @default.
• W2083670462 hasRelatedWork W2345888787 @default.
• W2083670462 hasRelatedWork W2419226942 @default.
• W2083670462 hasRelatedWork W2543795704 @default.
• W2083670462 hasRelatedWork W2563972134 @default.
• W2083670462 hasRelatedWork W2741532687 @default.
• W2083670462 hasRelatedWork W2792486916 @default.
• W2083670462 hasRelatedWork W2887268276 @default.
• W2083670462 hasRelatedWork W2912786319 @default.
• W2083670462 hasRelatedWork W2954164007 @default.
• W2083670462 hasRelatedWork W2982475794 @default.
• W2083670462 hasRelatedWork W3030716517 @default.
• W2083670462 hasRelatedWork W3092647873 @default.
• W2083670462 hasRelatedWork W3115042298 @default.
• W2083670462 hasRelatedWork W3172686185 @default.
• W2083670462 hasRelatedWork W4225346668 @default.
• W2083670462 isParatext "false" @default.
• W2083670462 isRetracted "false" @default.
• W2083670462 magId "2083670462" @default.
• W2083670462 workType "article" @default.